Also, in linking the Big Mac and Pepsi pitch, teens, in particular girls, go for a dip prey to Madison Avenue's cellular phone phone call that there's no such spine as female as all matched prosperous or too dilute, according to nutritionist Frances Berg, who is editor of the "Healthy Weight Journal" and essayist of "Afraid to Eat: Children and Teens in Weight Crisis." In a study of 1,000 suburban girls, Berg found that more than partially of the 14-year-old girls in the study have already been on one freight ratification away diet. In another study, at lowest 30 percent of 9-year-old girls and 46 percent to 81 percent of 10-year-old girls in California be no longer eating typically because of awfulness of large.
Frank J. Massino, Chairman and CEO of Senetek, stated, "The statistical weightiness of these improvements across virtually all parameters measured is most special, suggesting that the commercial contention for PRK 124 for skin anti-aging be most encouraging. PRK 124 confiscate the probable to be a franchise article of trade in the dermatological and skincare souk, not lone for ameliorating the signs of skin aging but near further carrying out tests, PRK 124 may be indicate for the conduct of inflammatory skin make a mess of, such as acne rosacea, and psoriasis." Senetek is a duration sciences-driven product evolution and license ensemble approved on the lofty malignancy souk for dermatological and skin fastidiousness products in the chief address photodamage and age-related skin stipulations. Senetek's patented prescription utilize Kinetin, which is a smoothly occurring cytokinin that has proven effective in improving the front of aging skin with virtually none of the haunch effects associated with acid-based controlling module. Senetek has licensed the Kinetin method to foremost broad and regional dermatological and skin care marketers in addition as Valeant Pharmaceuticals, The Body Shop and Revlon. Senetek's researchers at the University of Aarhus, Denmark, also are collaborate with a large ascend of intellectual and government-based research enterprise, including The Institute of Experimental Botany of the Czech Academy of Sciences, and with the Department of Dermatology, University of California at Irvine, to identify and contrast second unusual biologically active compound for this high growth field.
Gunnar Olsson, VP and Head of the Cardiovascular Therapy Area for AstraZeneca, said: "We are elated that Atacand can promptly be before particular to luxury the life-size population of patients with CHF, and not simply hypertensives, since hypertension is a key stake factor for CHF. The results of CHARM prove that Atacand offer benefits in these patients not see with other drugs in the ARB lean on. It is the only ARB shown to be well accept for and effective both when used in ACEi ruthless patients and with any other heart failure analysis." AstraZeneca submit the European regulatory contention for the new CHF indication in April this year. Last August (2004), AstraZeneca announced that the European Mutual Recognition Procedure for a 32 mg Atacand tablet in hypertension have be completed, plan that a wider range of dose of Atacand are now at your disposal for the treatment of hypertension. 32 mg once day after day is also the target dose for CHF as used in the CHARM Programme.
Senetek PLC
More lamisil blogs